Applicant: Michael J. Detmar et al.

Serial No.: 09/536,087 : March 24, 2000

Page

: 3 of 22

Attorney's Docket No.: 10287-051001 / MGH 1470.0

## Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

## Listing of Claims:

1. (Currently amended) A method of treating a subject having a disorder characterized by unwanted-cell proliferation an angiogenesis-dependent tumor, the method comprising administering to the subject a TSP-2 comprising an amino acid sequence at least 90% identical to the sequence of SEQ ID NO:2, or a fragment thereof capable of inhibiting endothelial cell migration, wherein the fragment comprises at least 10 contiguous amino acids of either (a) a procollagen domain of TSP-2, or (b) a type I repeat of TSP-2.



- 2.-5. (Canceled)
- 6. (Previously presented) The method of claim 1, wherein the fragment comprises the sequence of SEQ ID NO:10 (WSPWAEW).
  - 7.-13. (Canceled)
- (Currently amended) The method of claim 13, wherein the disorder affects tumor is an epithelial tissue tumor.
- 15. (Currently amended) The method of claim 1, wherein the disorder tumor is characterized by unwanted a skin tumor cell proliferation.

Applicant: Michael J. Detmar et al.

Serial No.: 09/536,087 Filed: March 24, 2000

Page : 4 of 22

- 16. (Currently amended) The method of claim 15, wherein the disorder turnor is a squamous cell carcinoma of the skin or a malignant melanoma.
- 17. (Currently amended) The method of claim 1, wherein the disorder tumor is characterized by unwanted a prostate cell proliferation tumor.
- 18. (Currently amended) The method of claim 1, wherein the disorder tumor is characterized by a benign unwanted skin proliferation tumor.
  - (Canceled)
    - 20. (Original) The method of claim 1, further comprising increasing TSP-1 activity.
- 21. (Original) The method of claim 1 or claim 20, further comprising inhibiting VEGF activity.
- 22. (Original) The method of claim 1, further comprising administering a chemotherapeutic agent.
- 23. (Original) The method of claim 22, wherein the chemotherapeutic agent is taxol or carboplatin.

## / 24.-52. (Canceled)

53. (Previously presented) The method of claim 1, wherein the fragment is up to 100 amino acids in length.

Applicant: Michael J. Detmar et al.

Serial No.: 09/536,087 Filed: March 24, 2000

Page : 5 of 22

- 54. (Previously presented) The method of claim 53, wherein the fragment is up to 50 amino acids in length.
- 55. (Previously presented) The method of claim 1, wherein the fragment is at least 50 amino acids in length.
- 56. (Previously presented) The method of claim 1, wherein the fragment is at least 100 amino acids in length.
- 57. (Previously presented) The method of claim 1, wherein the fragment is at least 200 amino acids in length.
- 58. (Previously presented) The method of claim 1, wherein the fragment comprises at least one type I repeat.
- (Previously presented) The method of claim 1, wherein the fragment includes between about 5 to 50 amino acids of a type I repeat.
- 60. (Previously presented) The method of claim 1, wherein the fragment comprises at least one sequence selected from the group of: amino acids 382-429 of SEQ ID NO:2, amino acids 438-490 of SEQ ID NO:2, and amino acids 495-547 of SEQ ID NO:2.
- 61. (Previously presented) The method of claim 1, wherein the fragment comprises SEQ ID NO:11.
  - 62. (Canceled)

Applicant: Michael J. Detmar et al.

Serial No.: 09/536,087 Filed: March 24, 2000

Page : 6 of 22

Attorney's Docket No.: 10287-051001 / MGH 1470.0

- 63. (Previously presented) The method of claim 1, wherein the fragment comprises a procollagen domain or a fragment thereof having the ability to inhibit endothelial cell migration.
- 64. (Previously presented) The method of claim 1, wherein the fragment comprises SEQ ID NO:6.
- 65. (Previously presented) The method of claim 1, wherein the fragment comprises SEQ ID NO:7.
- 66. (Previously presented) The method of claim 1, wherein the fragment comprises SEQ ID NO:8.
- 67. (Previously presented) The method of claim 1, wherein the fragment comprises SEQ ID NO:9.

## / 68.-74. (Canceled)

- 75. (Previously presented) The method of claim 1, wherein the fragment comprises two type I repeats.
- 76. (Previously presented) The method of claim 1, wherein the fragment comprises three type I repeats.
- 77. (Previously presented) The method of claim 1, wherein the fragment comprises an property amino acid sequence encoded by nucleotides 294-1367 of SEQ ID NO:1.
- 78. (Previously presented) The method of claim 1, wherein the fragment comprises an amino acid sequence encoded by nucleotides 294-1883 of SEQ ID NO:1.

Applicant: Michael J. Detmar et al.

Serial No.: 09/536,087 Filed: March 24, 2000

Page : 7 of 22

79. (Previously presented) The method of claim 1, wherein the fragment comprises an amino acid sequence encoded by nucleotides 1383-1883 of SEQ ID NO:1.

29

- 80. (Currently amended) The method of claim 1, wherein the disorder <u>tumor</u> is a colon eaneer <u>tumor</u>.
- 81. (Currently amended) The method of claim 1, wherein the disorder tumor is a breast eaneer tumor.
- 82. (Currently amended) The method of claim 1, wherein the disorder tumor is a lung cancer tumor.
- 83. (Currently amended) The method of claim 1, wherein the disorder tumor is Kaposi's sarcoma.
- 84. (Previously presented) The method of claim 1, wherein the TSP-2 has an amino acid sequence at least 95% identical to the sequence of SEQ ID NO:2.
- 85. (Previously presented) The method of claim 1, wherein the TSP-2 has an amino acid sequence at least 98% identical to the sequence of SEQ ID NO:2.
- 86. (Previously presented) The method of claim 1, wherein the TSP-2 has an amino acid sequence at least 99% identical to the sequence of SEQ ID NO:2.
- 87. (Currently amended) A method of treating a subject having a disorder elaracterized by unwanted cell proliferation an angiogenesis-dependent tumor, the method comprising:

Applicant: Michael J. Detmar et al.

Serial No.: 09/536,087 Filed: March 24, 2000

Page : 8 of 22

identifying a subject having a disorder characterized by unwanted cell proliferation an angiogenesis-dependent tumor; and

administering to the subject a polypeptide comprising the amino acid sequence of SEQ ID NO:2 (TSP-2) or a fragment thereof capable of inhibiting endothelial cell migration, wherein the fragment comprises at least 10 contiguous amino acids of either (a) a procollagen domain of TSP-2, or (b) a type I repeat of TSP-2.

- 88. (New) The method of claim 87, wherein the fragment comprises the sequence of SEQ ID NO:10 (WSPWAEW).
  - 89. (New) The method of claim 87, wherein the tumor is an epithelial tissue tumor.
  - 90. (New) The method of claim 87, wherein the tumor is a skin tumor.
  - 91. (New) The method of claim 90, wherein the tumor is a squamous cell carcinoma of the skin or a malignant melanoma.
    - 92. (New) The method of claim 87, wherein the tumor is a prostate tumor.
    - 93. (New) The method of claim 87, wherein the tumor is a benign skin tumor.
    - 94. (New) The method of claim 87, further comprising increasing TSP-1 activity.
  - 95. (New) The method of claim 87 or claim 94, further comprising inhibiting VEGF activity.
  - 96. (New) The method of claim 87, further comprising administering a chemotherapeutic agent.

IARDSON-

Applicant: Michael J. Detmar et al.

Serial No.: 09/536,087 Filed: March 24, 2000

Page : 9 of 22

Attorncy's Docket No.: 10287-051001 / MGH 1470.0

- 97. (New) The method of claim 96, wherein the chemotherapeutic agent is taxol or carboplatin.
- 98. (New) The method of claim 87, wherein the fragment is up to 100 amino acids in length.
- 99. (New) The method of claim 98, wherein the fragment is up to 50 amino acids in length.
- 100. (New) The method of claim 87, wherein the fragment is at least 50 amino acids in length.
- 101. (New) The method of claim 87, wherein the fragment is at least 100 amino acids in length.
- 102. (New) The method of claim 87, wherein the fragment is at least 200 amino acids in length.
- 103. (New) The method of claim 87, wherein the fragment comprises at least one type I repeat.
- 104. (New) The method of claim 87, wherein the fragment includes between about 5 to 50 amino acids of a type I repeat.
- 105. (New) The method of claim 87, wherein the fragment comprises at least one sequence selected from the group of: amino acids 382-429 of SEQ ID NO:2, amino acids 438-490 of SEQ ID NO:2, and amino acids 495-547 of SEQ ID NO:2.



Applicant: Michael J. Detmar et al.

Serial No.: 09/536,087

: March 24, 2000

Page

: 10 of 22

Attorney's Docket No.: 10287-051001 / MGH 1470.0

- 106. (New) The method of claim 87, wherein the fragment comprises SEQ ID NO:11.
- 107. (New) The method of claim 87, wherein the fragment comprises a procollagen domain or a fragment thereof having the ability to inhibit endothelial cell migration.
  - 108. (New) The method of claim 87, wherein the fragment comprises SEQ ID NO:6.
  - (New) The method of claim 87, wherein the fragment comprises SEQ ID NO:7. 109.
  - 110. (New) The method of claim 87, wherein the fragment comprises SEQ ID NO:8.
  - 111. (New) The method of claim 87, wherein the fragment comprises SEQ ID NO:9.
- 112. (New) The method of claim 87, wherein the fragment comprises a fragment of SEQ ID NO:10 at least 4 amino acids in length.
- 113. (New) The method of claim 87, wherein the fragment comprises two type I repeats.
- 114. (New) The method of claim 87, wherein the fragment comprises three type I repeats.
- (New) The method of claim 87, wherein the fragment comprises an amino acid 115. sequence encoded by nucleotides 294-1367 of SEQ ID NO:1.
- 116. (New) The method of claim 87, wherein the fragment comprises an amino acid sequence encoded by nucleotides 294-1883 of SEQ ID NO:1.

Applicant: Michael J. Detmar et al.

Serial No.: 09/536,087 Filed: March 24, 2000

Page : 11 of 22

117. (New) The method of claim 87, wherein the fragment comprises an amino acid sequence encoded by nucleotides 1383-1883 of SEQ ID NO:1.

- 118. (New) The method of claim 87, wherein the tumor is a colon tumor.
- 119. (New) The method of claim 87, wherein the tumor is a breast tumor.
- 120. (New) The method of claim 87, wherein the tumor is a lung tumor.
- 121. (New) The method of claim 87, wherein the tumor is Kaposi's sarcoma.
- 122. (New) A method of treating an angiogenesis-dependent tumor, the method comprising administering to the subject a fragment of TSP-2 consisting of the sequence of SEQ ID NO: 10 (WSPWAEW).